Skip to main content
. 2023 Feb 1;44(7):1475–1486. doi: 10.1038/s41401-023-01053-2

Fig. 3. 143D selectively inhibits the constitutive activation of KRASG12C signaling pathways.

Fig. 3

a Western blot analysis of KRAS signaling pathway components in MIA PaCa-2 and NCI-H1373 cells treated with 143D, MRTX849 or AMG510 for 12 h. b Western blot analysis of KRAS pathway targets in MIA PaCa-2 and NCI-H1373 cells treated with 30 nM 143D or MRTX849 for the indicated times. c Western blot analysis of KRAS pathway targets in Ba/F3 cells transfected with KRASG12C or KRASG12D after 143D, MRTX849 or AMG510 treatment for 12 h.